Compare ELMD & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELMD | LYEL |
|---|---|---|
| Founded | 1992 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.1M | 195.8M |
| IPO Year | 2010 | 2021 |
| Metric | ELMD | LYEL |
|---|---|---|
| Price | $23.00 | $13.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $48.50 | $37.63 |
| AVG Volume (30 Days) | 38.8K | ★ 212.6K |
| Earning Date | 11-10-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.94 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $54,716,000.00 | $36,000.00 |
| Revenue This Year | $11.55 | N/A |
| Revenue Next Year | $10.94 | N/A |
| P/E Ratio | $72.69 | ★ N/A |
| Revenue Growth | ★ 13.83 | N/A |
| 52 Week Low | $22.67 | $7.20 |
| 52 Week High | $47.40 | $45.00 |
| Indicator | ELMD | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 27.51 | 54.63 |
| Support Level | $23.03 | $12.25 |
| Resistance Level | $24.99 | $14.97 |
| Average True Range (ATR) | 1.24 | 1.67 |
| MACD | -0.29 | -0.18 |
| Stochastic Oscillator | 8.17 | 43.74 |
Electromed Inc is a United States-based company that develops, manufactures and markets airway clearance products that apply High Frequency Chest Wall Oscillation (HFCWO) therapy in pulmonary care for patients of all ages. The company markets its products in the U.S. to the homecare and hospital markets. Its product includes the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The company operates in a single segment: developing, manufacturing, and marketing medical equipment. The company generates revenue from Homecare, Hospital, Homecare Distributor, and Other.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.